S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NASDAQ:RDNT - RadNet Stock Price, Forecast & News

$22.03
+0.17 (+0.78 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$21.86
Now: $22.03
$22.35
50-Day Range
$20.20
MA: $21.86
$23.11
52-Week Range
$11.60
Now: $22.03
$23.45
Volume261,454 shs
Average Volume281,181 shs
Market Capitalization$1.11 billion
P/E Ratio32.88
Dividend YieldN/A
Beta0.92
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$975.15 million
Cash Flow$2.14 per share
Book Value$4.10 per share

Profitability

Net Income$32.24 million

Miscellaneous

Employees7,869
Market Cap$1.11 billion
Next Earnings Date3/12/2020 (Confirmed)
OptionableOptionable

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.


RadNet (NASDAQ:RDNT) Frequently Asked Questions

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) announced its earnings results on Tuesday, November, 12th. The medical research company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.11 by $0.05. The medical research company had revenue of $292.70 million for the quarter, compared to analysts' expectations of $283.39 million. RadNet had a return on equity of 16.52% and a net margin of 3.02%. The business's revenue was up 20.9% on a year-over-year basis. During the same quarter last year, the business posted $0.10 earnings per share. View RadNet's Earnings History.

When is RadNet's next earnings date?

RadNet is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for RadNet.

How can I listen to RadNet's earnings call?

RadNet will be holding an earnings conference call on Thursday, March 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for RDNT?

2 analysts have issued 12-month price targets for RadNet's shares. Their forecasts range from $17.50 to $28.00. On average, they expect RadNet's stock price to reach $22.75 in the next year. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for RadNet.

What is the consensus analysts' recommendation for RadNet?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RadNet.

Has RadNet been receiving favorable news coverage?

Media coverage about RDNT stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. RadNet earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for RadNet.

Are investors shorting RadNet?

RadNet saw a drop in short interest during the month of February. As of February 14th, there was short interest totalling 842,400 shares, a drop of 27.4% from the January 30th total of 1,160,000 shares. Based on an average trading volume of 540,900 shares, the short-interest ratio is currently 1.6 days. Currently, 2.0% of the shares of the stock are sold short. View RadNet's Current Options Chain.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Who are RadNet's key executives?

RadNet's management team includes the folowing people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division

Who are RadNet's major shareholders?

RadNet's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (6.62%), Renaissance Technologies LLC (3.51%), State Street Corp (2.42%), Beck Mack & Oliver LLC (2.11%), Global Alpha Capital Management Ltd. (2.04%) and Dalton Greiner Hartman Maher & Co. (1.68%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Institutional Ownership Trends for RadNet.

Which major investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Global Alpha Capital Management Ltd., Royce & Associates LP, Cheyne Capital Management UK LLP, Russell Investments Group Ltd., Cadence Capital Management LLC, Alliancebernstein L.P. and Assenagon Asset Management S.A.. Company insiders that have sold RadNet company stock in the last year include David L Swartz, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Insider Buying and Selling for RadNet.

Which major investors are buying RadNet stock?

RDNT stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Principal Financial Group Inc., State Street Corp, Bank of New York Mellon Corp, Punch & Associates Investment Management Inc., Candriam Luxembourg S.C.A., Public Sector Pension Investment Board and Citigroup Inc.. View Insider Buying and Selling for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $22.03.

How big of a company is RadNet?

RadNet has a market capitalization of $1.11 billion and generates $975.15 million in revenue each year. The medical research company earns $32.24 million in net income (profit) each year or $0.66 on an earnings per share basis. RadNet employs 7,869 workers across the globe.View Additional Information About RadNet.

What is RadNet's official website?

The official website for RadNet is http://www.radnet.com/.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]


MarketBeat Community Rating for RadNet (NASDAQ RDNT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  572
MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel